BP, United Arab Emirates (CNN) – Vaccination consultants at the US Food and Drug Administration voted Friday on the agency’s recommendation for emergency use of the Coronavirus vaccine from Johnson & Johnson.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the Food and Drug Administration voted unanimously to recommend granting Emergency Use Authorization (EUA) for a vaccine to persons aged 18 years and over.
Acting FDA Commissioner, Dr. Janet Woodcock, and Dr. Peter Marks, who heads the vaccines division at the FDA, said permission for emergency use would come quickly.
This will become the third vaccine approved for use in the United States.
The vaccine will become the first vaccine taken in a single dose, and it can be stored in regular refrigerators, which is easy to distribute compared to both “Pfizer-Biontec” and “Moderna”, which are considered more sensitive, and they require two doses.
The vaccine, produced by Janssen, the vaccine arm of Johnson & Johnson, was tested in advanced clinical trials on more than 44,000 people in the United States, South Africa, and Latin America.
Globally, the vaccine showed an overall effectiveness of 66% in preventing moderate to severe diseases.
In the United States, the effectiveness reached 72%, and it was 85% effective in preventing severe disease.